Stocks · News reference
Pasithea Therapeutics reported positive clinical data from its ongoing Phase 1 study of PAS-004, a macrocyclic MEK inhibitor, presented at the ESMO Congress 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pasithea Therapeutics has received FDA clearance for its Investigational New Drug (IND) application to begin clinical development of PAS-004 for the treatment of NF1-associated cutaneous neurofibromas.
Pasithea Therapeutics announced it will host a virtual key opinion leader event on November 4, 2026, to discuss the treatment landscape for neurofibromatosis type 1 (NF1) and the progress of its lead candidate, PAS-004.
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term
Gainers Picard Medical (AMEX:PMI) stock rose 40.2% to $4.5 during Friday's after-market session. The company's market cap stands at $6.2 million. As per the news, the Q2 earnings report came out 2 days ago.
Filed: 2026-08-21 AccNo: 0001213900-26-092672 Size: 240 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing